Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON
Launched by FUNDACIÓN CARDIOVASCULAR DE COLOMBIA · Jan 26, 2007
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
Background
Diabetes Mellitus (DM) constitutes one of the most important public health problems with a worldwide impact due to its high prevalence and enormous social and economic consequences. It is believed that there are more than 135 million diabetics, and this number is expected to increase to 300 million in the next 25 years (30% in developed and 70% in developing countries) \[1;2\].
This epidemic is related to several factors like ethnicity, the longer life expectancy, and the epidemiological and nutritional transition in developing countries due to the urbanization process that bri...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women 18 years or older.
- • Capacity of attending the visits at the research site.
- • Confirmed diagnosis of DM type 1 or 2 according to the guidelines from the American Diabetes Association (ADA).
- • Presence of 1 or more DFU, less than 15cm in its biggest diameter, with a Texas University score ≤2.
- • Pharmacological treatment for glycemic control.
- • Willingness to participate in the study and to sign the informed consent form.
- Exclusion Criteria:
- • Unconfirmed DM diagnosis.
- • Any pathology that, based on the judgment of the researcher, could alter the course of DFU (neoplasias, immunological disorders, etc).
- • Renal insufficiency requiring dialysis treatment.
- • DFU with a Texas score \>2.
- • Infected DFU with clinical or paraclinical findings suggesting osteomyelitis.
- • Critical ischemia of IL diagnosed by Doppler ultrasound and defined by ankle/arm index \< 0.5.
- • Clinical findings suggesting complicated venous insufficiency of IL.
- • Distal necrosis of the limb with the ulcer.
- • Pregnant or breastfeeding women.
- • Mentally or neurologically disabled patients that are considered not fit to approve their participation in the study.
- • Refusal to give informed consent.
About Fundación Cardiovascular De Colombia
Fundación Cardiovascular de Colombia is a leading research institution dedicated to advancing cardiovascular health through innovative clinical trials and comprehensive patient care. Established with a commitment to improving cardiovascular outcomes, the foundation engages in cutting-edge research that fosters collaboration among healthcare professionals, researchers, and patients. By prioritizing scientific excellence and ethical standards, Fundación Cardiovascular de Colombia aims to contribute significantly to the global understanding of cardiovascular diseases, ultimately enhancing treatment options and patient quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bucaramanga, Santander, Colombia
Patients applied
Trial Officials
Patricio López-Jaramillo, MD, PhD
Principal Investigator
Fundacion Cardiovascular de Colombia
Daniel J Smith, PhD
Principal Investigator
The University of Akron
Sandra Y Silva, MD
Study Chair
Fundacion Cardiovascular de Colombia
Ligia C Rueda, MD
Study Chair
Fundacion Cardiovascular de Colombia
Gustavo A Márquez, MD
Study Chair
Fundacion Cardiovascular de Colombia
Marcos López, PhD
Study Chair
The University of Akron
Piyaporn Kampeerapappun
Study Chair
The University of Akron
Juan C Castillo, MD
Study Chair
Fundacion Cardiovascular de Colombia
Carlos A Calderon, PhD
Study Chair
Fundación Santandereana de Diabetes y Obesidad
Jaime Matute, MD
Study Chair
Instituto de Seguros Sociales
Christian F Rueda-Clausen, MD
Study Chair
Fundacion Cardiovascular de Colombia
Arturo Orduz, MD
Study Chair
Fundacion Cardiovascular de Colombia
Federico A Silva, MD
Study Chair
Fundacion Cardiovascular de Colombia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials